
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated substantial growth in sales, with a notable 40% increase in the third quarter of 2025 compared to the same period in 2024, driven by the success of key products such as Repatha and Tezspire, which both recorded impressive year-over-year increases in new prescriptions. The company is also increasing its investment in research and development, with a projected growth of over 20% in R&D expenditure for 2025, indicating a strong commitment to innovation and expansion. Additionally, Amgen raised its FY25 revenue guidance to a range of $35.8 billion to $36.6 billion, reflecting the ongoing strength and performance of its established franchises and recent acquisitions.
Bears say
Amgen's revenue growth is projected to be only around 1% in 2026 compared to 2025, largely due to significant anticipated sales declines of approximately 28% for Prolia and 39% for Xgeva. The company's research and development spending is expected to grow more mutedly relative to 2025, indicating constraints on future innovation and competitive positioning. Additionally, despite the potential of emerging products like MariTide and olpasiran, uncertainty surrounding their ability to compensate for declining revenues from established products creates a challenging outlook, particularly with impending loss of exclusivity for key franchises.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares